These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36125593)

  • 21. Infliximab or cyclosporine for severe ulcerative colitis.
    Hanauer SB
    Gastroenterology; 2005 Oct; 129(4):1358-9; author reply 1359. PubMed ID: 16230092
    [No Abstract]   [Full Text] [Related]  

  • 22. Rescue therapy with cyclosporine or infliximab is not associated with an increased risk for postoperative complications in patients hospitalized for severe steroid-refractory ulcerative colitis.
    Nelson R; Liao C; Fichera A; Rubin DT; Pekow J
    Inflamm Bowel Dis; 2014 Jan; 20(1):14-20. PubMed ID: 24297054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infliximab to treat severe ulcerative colitis.
    Cury DB; Cury Mde S; Elias GV; Mizsputen SJ
    World J Gastroenterol; 2009 Apr; 15(14):1771-3. PubMed ID: 19360923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Infliximab salvage therapy after cyclosporine in an acute flare of chronic ulcerative colitis.
    Lam EC; Bailey RJ
    Can J Gastroenterol; 2003 Mar; 17(3):198-200. PubMed ID: 12677271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe.
    Weisshof R; Ollech JE; El Jurdi K; Yvellez OV; Cohen RD; Sakuraba A; Dalal S; Pekow J; Rubin DT
    J Crohns Colitis; 2019 Sep; 13(9):1105-1110. PubMed ID: 30726894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An approach to acute severe ulcerative colitis.
    Sedano R; Quera R; Simian D; Yarur AJ
    Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):943-955. PubMed ID: 31648574
    [No Abstract]   [Full Text] [Related]  

  • 27. Infliximab or cyclosporine for severe ulcerative colitis.
    Järnerot G
    Gastroenterology; 2006 Jan; 130(1):286; author reply 287. PubMed ID: 16401502
    [No Abstract]   [Full Text] [Related]  

  • 28. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease.
    Renna S; Cottone M; Orlando A
    World J Gastroenterol; 2014 Aug; 20(29):9675-90. PubMed ID: 25110407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What is the importance of infliximab and cyclosporine in the treatment of corticosteroid-refractory severe ulcerative colitis?
    Bengi G; Akpinar H
    Turk J Gastroenterol; 2012; 23 Suppl 2():7-12. PubMed ID: 23576083
    [No Abstract]   [Full Text] [Related]  

  • 30. Ulcerative Colitis: Update on Medical Management.
    Iskandar HN; Dhere T; Farraye FA
    Curr Gastroenterol Rep; 2015 Nov; 17(11):44. PubMed ID: 26386686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
    Kobayashi T; Hoshi M; Yuasa A; Arai S; Ikeda M; Matsuda H; Kim SW; Hibi T
    Pharmacoeconomics; 2023 May; 41(5):589-604. PubMed ID: 36884164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis.
    Shaffer SR; Huang E; Patel S; Rubin DT
    Am J Gastroenterol; 2021 Jan; 116(1):125-133. PubMed ID: 32947317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience.
    Verstockt B; Claeys C; De Hertogh G; Van Assche G; Wolthuis A; D'Hoore A; Vermeire S; Ferrante M
    United European Gastroenterol J; 2019 Nov; 7(9):1215-1225. PubMed ID: 31700634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved outcome of acute severe ulcerative colitis while using early predictors of corticosteroid failure and rescue therapies.
    Llaó J; Naves JE; Ruiz-Cerulla A; Gordillo J; Mañosa M; Maisterra S; Cabré E; Garcia-Planella E; Guardiola J; Domènech E
    Dig Liver Dis; 2016 Jun; 48(6):608-12. PubMed ID: 27012443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Biological agents in ulcerative colitis. When to prescribe].
    Barreiro-de Acosta M
    Gastroenterol Hepatol; 2011 Dec; 34 Suppl 3():36-42. PubMed ID: 25443225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of patients with severe glucocorticoid-refractory ulcerative colitis: cyclosporine or infliximab?].
    Löwenberg M; de Boer NK; Dewint P; Hoentjen F
    Ned Tijdschr Geneeskd; 2013; 157(38):A6130. PubMed ID: 24050446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis.
    Chu X; Biao Y; Liu C; Zhang Y; Liu C; Ma JZ; Guo Y; Gu Y
    BMC Gastroenterol; 2023 Oct; 23(1):346. PubMed ID: 37803294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life.
    Paschos P; Katsoula A; Salanti G; Giouleme O; Athanasiadou E; Tsapas A
    Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1174-1185. PubMed ID: 30378141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current and emerging biologics for ulcerative colitis.
    Park SC; Jeen YT
    Gut Liver; 2015 Jan; 9(1):18-27. PubMed ID: 25547087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Letter: ciclosporin or infliximab in acute ulcerative colitis - still undecided.
    Lopez-Sanroman A; Gisbert JP
    Aliment Pharmacol Ther; 2013 Oct; 38(8):992. PubMed ID: 24074311
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.